CCR5 and COVID-19: Another drug in development for COVID-19 is leronlimab, a C–C chemokine receptor type 5 (CCR5)-specific humanised IgG4 monoclonal antibody originally developed for the treatment of HIV for which it has been shown to be effective and well tolerated [[17], [18], [19]].